达标治疗干预后降尿酸治疗的现实世界持续性:STOP痛风试验的两年随访分析
本研究对完成72周STOP痛风试验的638例 participant(99%男性,平均年龄62.7岁)进行被动随访至研究结束后2年,发现66%仍持续降尿酸治疗;研究结束后≥2次风湿科就诊(vs 无)与更高持续性相关(aOR 1.75;95%CI 1.13-2.72),而黑种人/非裔美国人(aOR 0.56;95%CI 0.36-0.87)和西班牙裔(aOR 0.21;95%CI 0.09-0.50)持续性更低。
要点
- 研究结束后2年,66%的STOP痛风试验完成者仍持续降尿酸治疗。
- 研究结束后≥2次风湿科就诊者持续降尿酸治疗的可能性更高(aOR 1.75;95%CI 1.13-2.72)。
- 黑种人/非裔美国人(aOR 0.56;95%CI 0.36-0.87)和西班牙裔(aOR 0.21;95%CI 0.09-0.50)持续性更低。
核心结论
- 尽管实施达标治疗降尿酸治疗的干预在试验中显示有效,但本研究提示此类干预在转回现实世界痛风管理后可能持久性有限。
- 治疗持久性有限的问题在代表性不足的患者群体中似乎更为突出,而在持续风湿科诊疗背景下有所改善。
研究设计与样本
- 本研究为对完成72周STOP痛风试验且具备研究结束后2年随访数据的participant进行的分析,共纳入638例。
- participant通过行政和电子健康记录数据被动随访,持续性定义为与研究结束后2年时间点重叠的降尿酸治疗配药 episode。
- 采用多变量逻辑回归分析participant因素与降尿酸治疗持续性的关联。
主要发现
- 纳入分析的638例participant以男性为主(99%),平均年龄62.7岁。
- 研究结束后2年,66%的participant继续降尿酸治疗。
- 调整协变量后,研究结束后≥2次风湿科就诊(vs 无)与更高降尿酸治疗持续性相关(aOR 1.75;95%CI 1.13-2.72)。
- 报告黑种人/非裔美国人种(aOR 0.56;95%CI 0.36-0.87)和西班牙裔(aOR 0.21;95%CI 0.09-0.50)的个体降尿酸治疗持续性更低。
- 研究结束后随访开始时生活质量较好与降尿酸治疗持续性更低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Though gout guidelines endorse treat-to-target urate-lowering therapy (ULT), its long-term durability following treat-to-target implementation has not been extensively studied. Examining follow-up data from a trial implementing treat-to-target management, we evaluated the frequency and determinants of ULT persistence. METHODS: This analysis examined participants completing the 72-week STOP Gout trial with available follow-up data extending 2-years post-study. Participants were followed passively using administrative and electronic health record data with persistence defined by a ULT dispensing episode overlapping with the 2-year post-study time point. Associations of participant factors with ULT persistence were examined using multivariable logistic regression. RESULTS: Participants in this analysis (n = 638) were predominantly male (99 %) and had a mean age of 62.7 years. At 2-years post-study, 66 % continued ULT. Adjusting for covariates, ≥2 rheumatology visits post-study (vs. none) was associated with greater ULT persistence (aOR 1.75; 95 % CI 1.13-2.72). ULT persistence was lower in individuals reporting Black/African American race (aOR 0.56; 95 % CI 0.36-0.87), Hispanic ethnicity (aOR 0.21; 95 % CI 0.09-0.50), and better quality-of-life at the beginning of post-study follow-up. Though not reaching significance, achievement of serum urate goal at 48-weeks during STOP Gout study demonstrated a borderline association with greater long-term persistence (aOR 1.68; 95 % CI 0.99-2.85). CONCLUSION: Though interventions implementing treat-to-target ULT have demonstrated efficacy in trials, this study suggests that such interventions may have limited durability following transitions back to real-world gout management. The issue of limited treatment durability appears to be compounded among underrepresented patient populations and improved in the context of ongoing rheumatological care.
引用
- Kohn S, Sayles H, Helget LN, et al. Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum. 2025. PMID: 40782426. doi:10.1016/j.semarthrit.2025.152800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。